Evidence map›Paper›PMID 39051587›Full record

ReviewCurrent drug targets2024

New Perspectives in Colorectal Cancers Treatment, the Role of MicroRNAs.

Victoria A Belova, Liudmila V Spirina, Alexandra V Avgustinovich, Sergey G Afanas'ev, Maxim Y Volkov, Daniil I Azovsky, Alexander M Volkov, Tatyana S Klyushina

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current drug targets, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Victoria A BelovaDivision of Biochemistry and Molecular Biology, Siberian State Medical University, Tomsk, Russian Federation.ORCID 0009-0007-9820-9636
Liudmila V SpirinaDivision of Biochemistry and Molecular Biology, Siberian State Medical University, Tomsk, Russian Federation.
Alexandra V AvgustinovichCancer Research Institute, Tomsk National Research Medical Center of Russian Academy of Sciences, Tomsk, Russian Federation.ORCID 0000-0001-7301-7581
Sergey G Afanas'evCancer Research Institute, Tomsk National Research Medical Center of Russian Academy of Sciences, Tomsk, Russian Federation.ORCID 0000-0001-6066-3998
Maxim Y VolkovCancer Research Institute, Tomsk National Research Medical Center of Russian Academy of Sciences, Tomsk, Russian Federation.ORCID 0000-0001-6776-4898
Daniil I AzovskyCancer Research Institute, Tomsk National Research Medical Center of Russian Academy of Sciences, Tomsk, Russian Federation.ORCID 0000-0001-7375-9585
Alexander M VolkovCancer Research Institute, Tomsk National Research Medical Center of Russian Academy of Sciences, Tomsk, Russian Federation.ORCID 0009-0002-6969-7363
Tatyana S KlyushinaDivision of Biochemistry and Molecular Biology, Siberian State Medical University, Tomsk, Russian Federation.ORCID 0000-0003-3206-7800

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The main epidemiological and clinical data on colorectal cancer, as well as the features of molecular pathology, are discussed in the literature review. Efforts are being putto identify promising targets, particularly small non-coding nucleotide sequences, which can lead to new treatments for this disease. The discovery of significant mutations that contribute to the development of colorectal tumors is a major step in the advancement of molecular oncology, as these mutations give rise to heterogeneous tumors that differ in their origin. These mutations play a significant role in the progression of the disease and are now being targeted for treatment. The prognosis for a disease is influenced by the patient's sensitivity to antitumor therapy. However, new approaches to finding effective targets for antitumor treatments face new fundamental challenges due to clinical issues. These issues include the epigenetic regulation of markers of oncogenesis, which allows for the development of new therapeutic strategies. RNA interference, in particular, has been linked to non-copying RNA sequences such as microRNAs. These microRNAs are associated with certain processes that can influence all aspects of oncogenesis. The diversity of microRNAs allows for a differentiated approach when treating tumors in various locations.

Indexed as

Colorectal NeoplasmsMicroRNAsAntineoplastic AgentsBiomarkers, TumorEpigenesis, GeneticGene Expression Regulation, NeoplasticHumansMolecular Targeted TherapyMutationPrognosisAntineoplastic AgentsBiomarkers, TumorMicroRNAscolorectal cancergrowth factorsmicroRNAsmicrosatellite.oncogenestranscription factors

Identifiers

PMID39051587

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.